COL5A2 and urinary bladder cancer: COL5A2 is classified as a clinical biomarker for metastasis, such as gastric, colorectal, and bladder cancer, including osteosarcoma, and has been associated with the development of tumors in the immune system, proliferation, and angiogenesis [22,33,42,43,44].